关节镜下滑膜切除术与关节内注射糖皮质激素治疗难治性银屑病或类风湿关节炎腕关节病变:随机对照试验研究方案(ARCTIC试验)
本研究为前瞻性随机对照试验方案,纳入经风湿科医生确认存在明显腕关节滑膜炎、且至少3个月传统改善病情抗风湿药(DMARDs)治疗无应答、未使用过生物制剂的类风湿关节炎(RA)和银屑病关节炎(PsA)患者,按1:1随机接受关节镜下滑膜切除术并沉积糖皮质激素或关节内注射糖皮质激素(IACSI)。主要结局为3个月时患者腕关节评价量表(PRWE)评分,随访至12个月,评估腕功能、影像学进展、疾病活动度、生活质量、工作参与和成本效果。
要点
- 针对传统DMARDs至少3个月无应答且未用过生物制剂的RA或PsA腕关节滑膜炎患者。
- 按1:1随机接受关节镜下滑膜切除术并沉积糖皮质激素或关节内注射糖皮质激素。
- 主要结局为3个月时PRWE评分,随访3、6、12个月并做成本效果分析。
核心结论
- 这是首个在RA和PsA患者中比较关节镜下滑膜切除术与关节内注射糖皮质激素效果、安全性和可行性的随机对照试验。
研究设计与样本
- 前瞻性随机对照试验方案,纳入经风湿科医生客观确认存在明显腕关节滑膜炎、至少3个月传统DMARDs治疗无应答且未使用过生物制剂的RA和PsA患者。
- 按90%把握度、预期失访5%、PRWE评分均值差11分和α=0.05计算,总样本量80例足以检测效应量。
- 患者按1:1随机接受关节镜下滑膜切除术并沉积糖皮质激素或关节内注射糖皮质激素(IACSI)。
- 切除的滑膜组织将保存用于疾病分型的辅助研究。
- 随访安排在3、6和12个月,研究访视与常规随访合并以减轻患者负担。
主要发现
- 主要结局为3个月时采用PRWE评分(范围0-100)测量的腕功能。
- 次要结局包括腕关节活动度和握力、疼痛评分、DAS28、EQ-5D-5L、超声和X线片上的疾病进展、并发症和后续治疗。
- 将基于医疗费用(iMCQ问卷)和生产力损失(iPCQ问卷)进行成本效果分析。
关键数值与推荐
- 纳入标准:风湿科医生客观确认存在明显腕关节滑膜炎,至少3个月传统DMARDs治疗无应答,未使用过生物制剂。
- 主要结局:3个月时PRWE评分。
- 随访时间点:3、6和12个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are inflammatory diseases that often affect the wrist and, when affected, can lead to impaired wrist function and progressive joint destruction if inadequately treated. Standard care consists primarily of disease-modifying anti-rheumatic drugs (DMARDs), often supported by systemic corticosteroids or intra-articular corticosteroid injections (IACSI). IACSI, despite their use worldwide, show poor response in a substantial group of patients. Arthroscopic synovectomy of the wrist is the surgical removal of synovitis with the goal to relieve pain and improve wrist function. The primary objective of this study is to evaluate wrist function following arthroscopic synovectomy compared to IACSI in therapy-resistant patients with rheumatoid or psoriatic arthritis. Secondary objectives include radiologic progress, disease activity, health-related quality of life, work participation and cost-effectiveness during a 1-year follow-up. METHODS: This protocol describes a prospective, randomized controlled trial. RA and PsA patients are eligible with prominent wrist synovitis objectified by a rheumatologist, not responding to at least 3 months of conventional DMARDs and naïve to biological DMARDs. For 90% power, an expected loss to follow-up of 5%, an expected difference in mean Patient-Rated Wrist Evaluation score (PRWE, range 0-100) of 11 and α = 0.05, a total sample size of 80 patients will be sufficient to detect an effect size. Patients are randomized in a 1:1 ratio for arthroscopic synovectomy with deposition of corticosteroids or for IACSI. Removed synovial tissue will be stored for an ancillary study on disease profiling. The primary outcome is wrist function, measured with the PRWE score after 3 months. Secondary outcomes include wrist mobility and grip strength, pain scores, DAS28, EQ-5D-5L, disease progression on ultrasound and radiographs, complications and secondary treatment. Additionally, a cost-effectiveness analysis will be performed, based on healthcare costs (iMCQ questionnaire) and productivity loss (iPCQ questionnaire). Follow-up will be scheduled at 3, 6 and 12 months. Patient burden is minimized by combining study visits with regular follow-ups. DISCUSSION: Persistent wrist arthritis continues to be a problem for patients with rheumatic joint disease leading to disability. This is the first randomized controlled trial to evaluate the effect, safety and feasibility of arthroscopic synovectomy of the wrist in these patients compared to IACSI. TRIAL REGISTRATION: Dutch trial registry (CCMO), NL74744.100.20. Registered on 30 November 2020. CLINICALTRIALS: gov NCT04755127. Registered after the start of inclusion on 15 February 2021.
引用
- d'Ailly PN, Deugd C, Schep NWL, et al. Arthroscopic synovectomy versus intra-articular injection of corticosteroids for the management of refractory psoriatic or rheumatoid arthritis of the wrist: study protocol for a randomized controlled trial (ARCTIC trial). Trials. 2023. PMID: 36966310. doi:10.1186/s13063-023-07129-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。